This proliferative–antiapoptotic axis could partly explain the association of high PHH3 and XIAP levels with adverse clinicopathological parameters and supports the hypothesis that evaluating both markers together may provide a more comprehensive assessment of tumor biology than assessing either in isolation. This evidence concerns the gene XIAP and neoplasm.